Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morten Asser Karsdal

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
Expert Review of Proteomics|December 23, 2015
Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkersFederica Genovese, Morten Asser Karsdal
Drug Discovery Today|July 13, 2011
Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioningKim Henriksen, Claus Christiansen, Morten Asser Karsdal
Cancer Biology & Therapy|January 11, 2019
Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancerNicholas Willumsen, Lars Nannestad Jorgensen, Morten Asser Karsdal
Clinical and Experimental Rheumatology|October 18, 2019
Biochemical markers in osteoarthritis with lessons learned from osteoporosisMorten Asser Karsdal, Kim Henriksen, Anne Christine Bay-Jensen
Journal of Alzheimer'S Disease : JAD|August 30, 2014
Relationship between serum levels of tau fragments and clinical progression of Alzheimer's diseaseKim Henriksen, Inger Byrjalsen, Claus Christiansen, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 7, 2013
Menopause, estrogens and frailtyAnders Nedergaard, Kim Henriksen, Morten Asser Karsdal, et al.
Expert Opinion on Therapeutic Targets|May 12, 2015
Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disordersKim Henriksen, Christian Schneider Thudium, Claus Christiansen, et al.
Biomedicines|October 27, 2022
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist TherapyNina Sonne, Anna Thorsø Larsen, Morten Asser Karsdal, et al.
Journal of Cardiovascular Pharmacology|February 11, 2025
Decastatin, a Novel Non-Collagenous 1 Domain From Collagen Type X, Harbors a Specific Fragment With Antiangiogenic PropertiesStine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, et al.
Clinical Kidney Journal|February 10, 2025
Collagen type III formation but not degradation is associated with risk of kidney disease progression and mortality after acute kidney injuryNadja Sparding, Federica Genovese, Morten Asser Karsdal, et al.
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
Expert Review of Proteomics|December 23, 2015
Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkersFederica Genovese, Morten Asser Karsdal
Drug Discovery Today|July 13, 2011
Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioningKim Henriksen, Claus Christiansen, Morten Asser Karsdal
Cancer Biology & Therapy|January 11, 2019
Vastatin (the NC1 domain of human type VIII collagen a1 chain) is linked to stromal reactivity and elevated in serum from patients with colorectal cancerNicholas Willumsen, Lars Nannestad Jorgensen, Morten Asser Karsdal
Clinical and Experimental Rheumatology|October 18, 2019
Biochemical markers in osteoarthritis with lessons learned from osteoporosisMorten Asser Karsdal, Kim Henriksen, Anne Christine Bay-Jensen
Journal of Alzheimer'S Disease : JAD|August 30, 2014
Relationship between serum levels of tau fragments and clinical progression of Alzheimer's diseaseKim Henriksen, Inger Byrjalsen, Claus Christiansen, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|February 7, 2013
Menopause, estrogens and frailtyAnders Nedergaard, Kim Henriksen, Morten Asser Karsdal, et al.
Expert Opinion on Therapeutic Targets|May 12, 2015
Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disordersKim Henriksen, Christian Schneider Thudium, Claus Christiansen, et al.
Biomedicines|October 27, 2022
The Impact of Exposure Profile on the Efficacy of Dual Amylin and Calcitonin Receptor Agonist TherapyNina Sonne, Anna Thorsø Larsen, Morten Asser Karsdal, et al.
Journal of Cardiovascular Pharmacology|February 11, 2025
Decastatin, a Novel Non-Collagenous 1 Domain From Collagen Type X, Harbors a Specific Fragment With Antiangiogenic PropertiesStine Marie Jansen, Rastislav Pitek, Morten Asser Karsdal, et al.
Clinical Kidney Journal|February 10, 2025
Collagen type III formation but not degradation is associated with risk of kidney disease progression and mortality after acute kidney injuryNadja Sparding, Federica Genovese, Morten Asser Karsdal, et al.
Pageof 16